Investigated for treating COVID-19.
- TRADE NAME: Evista (Lilly)
- INDICATIONS: Osteoporosis; reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer
- CLASS: Selective estrogen receptor modulator (SERM)
- HALF-LIFE: 27.7 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cholestyramine, Levothyroxine
- See adverse reactions attributed to class:
INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 12/19/2023
